NLS Pharmaceutics Ltd. (NLSP) - Dilution Analysis

F-3 filing: This is a registration statement for the resale of up to 2,259,217 common shares by selling shareholders, which includes shares issuable upon conversion of preferred stock and exercise of warrants.

20-F filing | 4.8M shares outstanding

POS AM filing: This is a POS AM filing that discusses the company's cash flow for the six months ended June 30, 2025 and 2024, including details of private placement offerings and warrant exercises.

POS AM filing: This prospectus relates to the offer and sale of up to 5,000,000 of our common shares by Alpha Capital Anstalt, the selling shareholder.

POS AM filing: This is a POS AM filing providing an update on the company's financials, including cash flow, operating activities, and financing activities, as well as details of past securities purchase agreements and warrant amendments.

F-1 filing: This prospectus relates to the offer and sale of up to 5,000,000 of our common shares by Alpha Capital Anstalt, a Liechtenstein Anstalt, or Alpha (the "Selling Shareholder").

20-F filing | 3.2M shares outstanding

F-3 filing: NLS Pharmaceutics Ltd. is offering common shares, warrants, and units up to a total amount of $75,000,000.

F-3 filing: This prospectus relates to the resale by the Selling Shareholder identified in this prospectus of up to 645,161 of our Common Shares

F-3 filing: This F-3 filing is for the resale of up to 2,747,437 common shares by selling shareholders.

F-1 filing: This F-1 filing from 2024-08-27 discusses a registered direct offering of 3,277,750 Common Shares at a purchase price of $0.24 per share, which closed on July 1, 2024, along with concurrent private placement of warrants to purchase up to an aggregate of 3,277,750 Common Shares at an exercise of $0.24 per share.

F-1 filing: This F-1 filing relates to the resale of up to 3,500,000 Common Shares issuable upon the exercise of warrants issued in a private placement.

20-F filing | 38.2M shares outstanding

20-F filing | 32.4M shares outstanding

F-3 filing: NLS Pharmaceutics Ltd. is filing an F-3 to register the resale of up to 11,494,253 common shares by selling shareholders, consisting of shares held by the selling shareholders and shares issuable upon exercise of pre-funded warrants.

F-3 filing: This is an F-3 filing for NLS Pharmaceutics Ltd. relating to the resale of up to 11,874,690 common shares by selling shareholders, as well as shares issuable upon exercise of warrants.

F-1 filing: The filing discusses a registered direct offering and concurrent private placement where warrants to purchase common shares were issued. It also mentions a placement agent agreement and corporate information regarding the company's reorganization.

20-F filing | 16.2M shares outstanding

F-3 filing: NLS Pharmaceutics Ltd. may offer and sell from time to time in one or more offerings up to a total amount of $75,000,000 of its common shares, CHF 0.02 per share, or the Common Shares, warrants or units.

F-1 filing: This F-1 filing relates to the offer and sale of up to 1,474,853 common shares by YA II PN, LTD. pursuant to a Standby Equity Distribution Agreement (SEDA).

F-1 filing: This F-1 filing describes the offering and sale of up to 2,680,211 common shares by YA II PN, LTD., and the potential sale of up to $20.0 million of common shares to YA under a Standby Equity Distribution Agreement (SEDA).

POS AM filing: This POS AM filing relates to the offering of up to 5,409,746 Common Shares upon the exercise of IPO Warrants and Underwriter Warrants.

POS AM filing: NLSP is offering up to 5,409,746 common shares upon the exercise of IPO Warrants to purchase 4,542,277 Common Shares, plus an additional 722,891 warrants purchased pursuant to the exercise of an underwriters' overallotment option, and Underwriter Warrants to purchase 144,578 Common Shares.

20-F filing | 7.0M shares outstanding

F-1 filing: NLS Pharmaceutics Ltd. is offering its common shares in an initial public offering, and is also issuing warrants to Maxim Group LLC to purchase a number of shares equal to 3% of the total number of common shares sold in this offering.